BERLIN, June 29, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the results of its 2022 annual general meeting of shareholders (AGM), which took place on June 29, 2022, at 02.00 p.m. CEST. Shareholders representing a total of 9.33% of the total issued and outstanding share capital on June 1, 2022, were represented in person or by p
BERLIN, June 23, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces the start of the parity period on June 27, 2022, following the approval of share consolidation at the extraordinary general meeting of shareholders (EGM) on May 16, 2022.
BERLIN, June 23, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today an updated strategy to focus its capabilities on NOX-A12 in brain cancer (glioblastoma) and in particular on the triple combination of NOX-A12, radiotherapy and bevacizumab. This decision follows positive data generated in the GLORIA Phase 1/2 study, consisting of a dose-escalation